Linked Life Data

2973598

Source:http://linkedlifedata.com/resource/pubmed/id/2973598

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
37
pubmed:dateCreated
1989-1-5
pubmed:abstractText
In a preliminary study of 21 febrile episodes in neutropenic patients ceftazidime used as empirical treatment in doses of 3 grams per day succeeded in controlling fever in 74 per cent of the cases. Laboratory studies performed in patients with Gram-negative septicaemia showed clinically effective plasma concentrations of the antibiotic. A trial of ceftazidime (3 g/day) administered alone or combined with amikacin or vancomycin is currently in progress in two medical centres. No statistically significant conclusions could be reached from an intermediate study.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0755-4982
pubmed:author
pubmed:issnType
Print
pubmed:day
26
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
1968-70
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
[Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients].
pubmed:affiliation
Service d'Hématologie, Institut Gustave Roussy, Villejuif.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Randomized Controlled Trial